• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corporation - Common Stock (NQ:INCY)

    108.53 +0.70 (+0.65%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Incyte Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    28 29 Next >
    News headline image
    Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
    From Incyte
    Via Business Wire
    News headline image
    Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
    From Incyte
    Via Business Wire
    Top S&P500 movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Why Incyte (INCY) Stock Is Up Today
    What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.8% in the morning session after several analyst firms raised the... 
    Via StockStory
    Topics Artificial Intelligence
    Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
    Via Chartmill
    INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
    Via Chartmill
    Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗
    Via Chartmill
    News headline image
    2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
    The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
    Via StockStory
    Topics Credit Cards Stocks
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
    From Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    Wednesday's session: top gainers and losers in the S&P500 index ↗
    Via Chartmill
    These S&P500 stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
    From Incyte
    Via Business Wire
    News headline image
    3 Profitable Stocks for Long-Term Investors
    Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia... 
    Via StockStory
    News headline image
    Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From Incyte
    Via Business Wire
    News headline image
    Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
    Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody... 
    Via MarketBeat
    News headline image
    Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
    From Genesis Molecular AI and Incyte
    Via Business Wire
    News headline image
    Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
    From Incyte and Edison Scientific
    Via Business Wire
    News headline image
    Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗
    Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,... 
    Via MarketBeat
    News headline image
    Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
    From Incyte
    Via Business Wire
    News headline image
    2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore
    A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
    Via StockStory
    News headline image
    Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Incyte Corporation
    Via Business Wire
    News headline image
    Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hemat... 
    Via StockStory
    Topics Earnings
    News headline image
    Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    News headline image
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    News headline image
    INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
    Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 bi... 
    Via StockStory
    News headline image
    Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
    Incyte (INCY) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Incyte (INCY) Q2 2025 Earnings Transcript ↗
    Incyte (INCY) Q2 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
    Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on... 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    28 29 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.